ProArc Medical
Minimally Invasive Devices for Benign Prostatic Hyperplasia
Company Overview
Snapshot
Founded in July 2010 by Yair Feld, ProArc Medical operates with 1–10 employees. The company has raised $2.28M across 4 funding rounds from 2 investors. In July 2019, ProArc Medical was awarded a $2.2 million grant from the European Union.
Business overview
ProArc Medical is a medical device company focused on developing and commercializing non-invasive solutions for benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. Its core product, ClearRing, is a prostatic reshaping device designed to alleviate lower urinary tract symptoms caused by BPH. The device utilizes a nitinol implant in an open ring shape, delivered via a dedicated system compatible with standard cystoscopes. ProArc Medical serves the healthcare industry, specifically targeting urology and medical treatment providers with its implant-based technology.
Strategic signal
In July 2019, ProArc Medical secured a $2.2 million grant from the European Union. This significant non-equity funding validates the potential of its ClearRing device for treating benign prostatic hyperplasia and signals strong European interest in its minimally invasive approach, potentially accelerating clinical development and market entry within the region.
Log in to access full profile ›Company Intelligence Q&A
- What is ProArc Medical's primary focus?
- ProArc Medical specializes in developing and commercializing noninvasive medical devices for the treatment of benign prostatic hyperplasia (BPH), also known as enlarged prostate.
- What is the ClearRing device?
- The ClearRing device is a prostatic reshaping device developed by ProArc Medical. It uses a nitinol implant in an open ring shape to expand obstructed areas in the enlarged prostate, aiming to treat lower urinary tract symptoms from BPH.
- When was ProArc Medical founded and by whom?
- ProArc Medical was founded in July 2010 by Yair Feld.
- Has ProArc Medical received any significant grants?
- Yes, in July 2019, ProArc Medical was awarded a $2.2 million grant from the European Union. Additionally, in January 2018, the company received a grant from the Israel Innovation Authority.